Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society

Simple item page
dc.contributor.authorWild, R.
dc.contributor.authorCarmina, E.
dc.contributor.authorDiamanti-Kandarakis, E.
dc.contributor.authorDokras, A.
dc.contributor.authorEscobar-Morreale, H.
dc.contributor.authorFutterweit, W.
dc.contributor.authorLobo, R.
dc.contributor.authorNorman, R.
dc.contributor.authorTalbott, E.
dc.contributor.authorDumesic, D.
dc.date.issued2010
dc.description.abstractObjective: Women with polycystic ovary syndrome (PCOS) often have cardiovascular disease (CVD) risk factors. The Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society created a panel to provide evidence-based reviews of studies assessing PCOS-CVD risk relationships and to develop guidelines for preventing CVD. Participants: An expert panel in PCOS and CVD reviewed literature and presented recommendations. Evidence: Only studies comparing PCOS with control patients were included. All electronic databases were searched; reviews included individual studies/databases, systematic reviews, abstracts, and expert data. Articles were excluded if other hyperandrogenic disorders were not excluded, PCOS diagnosis was unclear, controls were not described, or methodology precluded evaluation. Inclusion/exclusion criteria were confirmed by at least two reviewers and arbitrated by a third. Consensus Process: Systematic reviews of CVD risk factors were compiled and submitted for approval to the AE-PCOS Society Board. Conclusions: Women with PCOS with obesity, cigarette smoking, dyslipidemia, hypertension, impaired glucose tolerance, and subclinical vascular disease are at risk, whereas those with metabolic syndrome and/or type 2 diabetes mellitus are at high risk for CVD. Body mass index, waist circumference, serum lipid/glucose, and blood pressure determinations are recommended for all women with PCOS, as is oral glucose tolerance testing in those with obesity, advanced age, personal history of gestational diabetes, or family history of type 2 diabetes mellitus. Mood disorder assessment is suggested in all PCOS patients. Lifestyle management is recommended for primary CVD prevention, targeting low-density and non-high-density lipoprotein cholesterol and adding insulin-sensitizing and other drugs if dyslipidemia or other risk factors persist.
dc.description.statementofresponsibilityRobert A. Wild, Enrico Carmina, Evanthia Diamanti-Kandarakis, Anuja Dokras, Hector F. Escobar-Morreale, Walter Futterweit, Rogerio Lobo, Robert J. Norman, Evelyn Talbott and Daniel A. Dumesic
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism, 2010; 95(5):2038-2049
dc.identifier.doi10.1210/jc.2009-2724
dc.identifier.issn0021-972X
dc.identifier.issn0021-972X
dc.identifier.orcidNorman, R. [0000-0002-3118-3896]
dc.identifier.urihttp://hdl.handle.net/2440/59930
dc.language.isoen
dc.publisherEndocrine Society
dc.rightsCopyright © 2010 by The Endocrine Society
dc.source.urihttps://doi.org/10.1210/jc.2009-2724
dc.subjectHumans
dc.subjectPolycystic Ovary Syndrome
dc.subjectCardiovascular Diseases
dc.subjectDiabetes Mellitus, Type 2
dc.subjectGlucose Intolerance
dc.subjectBody Mass Index
dc.subjectWaist-Hip Ratio
dc.subjectRisk Assessment
dc.subjectRisk Factors
dc.subjectFemale
dc.subjectAtherosclerosis
dc.titleAssessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Obstetrics and Gynaecology publications